Approach and Management of Patients with Chronic Hepatitis B and C During the Course of Inflammatory Bowel Disease

Coban S., KEKİLLİ M., Koklu S.

INFLAMMATORY BOWEL DISEASES, cilt.20, sa.11, ss.2142-2150, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 20 Sayı: 11
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1097/mib.0000000000000126
  • Dergi Adı: INFLAMMATORY BOWEL DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2142-2150
  • Anahtar Kelimeler: inflammatory bowel disease, ulcerative colitis, Crohn's disease, hepatitis B, hepatitis c, VIRUS-INFECTION, CROHNS-DISEASE, INTERFERON-ALPHA, PREEMPTIVE LAMIVUDINE, INFLIXIMAB THERAPY, ANTIVIRAL THERAPY, VACCINE BOOSTERS, NATURAL-HISTORY, RESPONSE RATE, DOUBLE-BLIND
  • Gazi Üniversitesi Adresli: Hayır

Özet

Inflammatory bowel disease and chronic viral hepatitis are 2 distinct but common conditions throughout the world. Mostly, both need lifelong follow-up. Since immunosuppressive drugs remain corner stones of inflammatory bowel disease management, one should be aware of the concomitant presence of chronic viral hepatitis in such patients to prevent serious (even fatal) outcomes. Recently, new treatment options have become available in the treatment of both inflammatory bowel disease and chronic viral hepatitis. In this review, we have discussed and summarized current treatment and follow-up strategies for those 2 important public health issues in light of available literature.